195,00 € – 695,00 €
Delivery Time: 3-5 business days
excl. VAT plus Shipping Costs
Synonyms = CK15; Cytokeratin 15; K1CO; Ka15; Keratin 15 basic; Keratin 15 beta; Keratin complex 1 acidic gene 15; Keratin type I cytoskeletal 15; KRT15; KRTB; KRTL15; Type I cytoskeletal 15; Type I keratin Ka15
Antibody type = Mouse monoclonal / IgG2b
Clone = MSVA-615M
Positive control = Tonsil: All cells of the surface squamous epithelium and most squamous cells of the crypts should show strong KRT15 staining.
Negative control = Tonsil: All lymphocytes and blood vessels must not show any KRT15 staining.
Cellular localization = Cytoplasmic
Reactivity = Human
Application = Immunohistochemistry
Dilution = 1:50 – 1:100
Intended Use = Research Use Only
Relevance of Antibody
Cytokeratin 15 is physiologically expressed in squamous epithelium and urothelium.
Cytokeratin 15 (CK15) also termed keratin 15 (KRT15) is a type I acidic high molecular weight keratin protein encoded by the KRT15 gene located 17q21.2. It dimerizes with the basic type II keratin 4 and forms intermediate filaments that primarily shape the cytoskeleton of specific epithelial cells. In these cells, KRT15 is part of the cytoskeletal scaffold which contributes to the cell architecture and provides the cells with the ability to withstand mechanical stress. KRT15 can be downregulated in activated keratinocytes.
Staining Pattern in Normal Tissues
A strong KRT15 immunostaining is found in all cell layers of all non-keratinizing and keratinizing squamous epithelium including hair follicles and sebaceous glands, acinar but not myoepithelial cells of the breast, amnion cells of the placenta, urothelium (stronger staining in lower half as compared to upper half), myoepithelial cells and basal cells of excretion ducts of all salivary glands and bronchial glands. In the prostate, epididymis, and the respiratory epithelium, KRT15 immunostaining is strong in all basal cells and occasionally also occurs in luminal epithelial cells. Only few basal cells are KRT15 positive in seminal vesicles. In the thymus, KRT15 is strongly expressed in Hassall’s corpuscles and medullary thymic epithelial cells but weaker in cortical thymic epithelial cells. KRT15 immunostaining can also be seen in the syncytiotrophoblast of the placenta (generally weak and more common in first trimenon than in mature placenta), occasionally in few cells of collecting ducts of the kidney, and in a fraction of epithelial cells of the adenohypophysis. A very weak KRT15 immunostaining can also be seen in gastric glands (apical predominance), intercalated ducts in the pancreas, and bronchial glands. KRT15 immunostaining is absent in colon, appendix, small intestine, gallbladder, liver, lung, fallopian tube, endometrium and endocervical glands of the uterus, ovary, lymphatic, hematopoetic and mesenchymal tissues, and the brain.
These findings are largely comparable to the RNA and protein data summarized in the Human Protein Atlas (Tissue expression Cytokeratin 15). We consider the KRT15 staining in colorectal mucosa found by using the antibody HPA024554 in the protein atlas as non-specific because it is not supported by RNA data, much less seen by using HPA023910, and not found by MSVA-615M.
Suggested positive tissue control: Tonsil: All cells of the surface squamous epithelium and most squamous cells of the crypts should show strong KRT15 staining.
Suggested negative tissue control: Tonsil: All lymphocytes and blood vessels must not show any KRT15 staining.
Staining Pattern in Relevant Tumor Types
KRT15 immunostaining almost exclusively occurs in squamous cell carcinomas of various sites of origin. At lower frequencies and lower levels, KRT15 expression can also be seen in other tumor types.
The TCGA findings on Cytokeratin 15 RNA expression in different tumor categories have been summarized in the Human Protein Atlas.
Compatibility of Antibodies
No data available at the moment
IHC users have different preferences on how the stains should look like. Some prefer high staining intensity of the target stain and even accept some background. Others favor absolute specificity and lighter target stains. Factors that invariably lead to more intense staining include higher concentration of the antibody and visualization tools, longer incubation time, higher temperature during incubation, higher temperature and longer duration of the heat induced epitope retrieval (slide pretreatment). The impact of the pH during slide pretreatment has variable effects and depends on the antibody and the target protein. Accordingly, multiple different protocols can generate identical staining results.
All images and data shown here and in our image galleries are obtained by the manual protocol described below. Other protocols resulting in equivalent staining are described as well.
Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH7,8 Target Retrieval Solution buffer. Apply MSVA-615M at a dilution of 1:50 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions.
-Impact of pH
MSVA-615M results in strongest staining if pH9,0 is used for slide pretreatment. pH7,8 is acceptable but lower pH results in a significant reduction of sensitivity.
Potential Research Applications
- Studies have suggested that reduced expression in squamous epithelium may be found in case of dysplasia or other pathologic changes. Further investigations on this subject are needed.
- The prognostic role of KRT15 expression in squamous cell carcinoma is unknown.
Evidence for Antibody Specificity in IHC
Specificity of MSVA-615M is documented by a staining pattern that exactly matches the data summarized in the protein atlas. As suggested by the protein atlas data, a strong positive KRT15 staining is seen in all keratinizing and non-keratinizing squamous epithelia. KRT15 staining in specific cell types is also found in other organs where the RNA data of the protein atlas suggest KRT15 expression such as salivary glands, prostate, and respiratory epithelium. In addition, all tissues known to not express KRT15 including those notorious for non-specific IHC background such as kidney and colonic mucosa are completely KRT15 negative.